These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26979012)

  • 21. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
    Goo AK; Carson DS; Bjelajac A
    J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound.
    Cheng AY; Josse RG
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1365-73. PubMed ID: 19642952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin: the past, presence, and future.
    Alušík Š; Paluch Z
    Minerva Med; 2015 Aug; 106(4):233-8. PubMed ID: 25532538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin.
    Bailey CJ; Turner RC
    N Engl J Med; 1996 Feb; 334(9):574-9. PubMed ID: 8569826
    [No Abstract]   [Full Text] [Related]  

  • 25. [Metformin role in the treatment of type 2 diabetes in 2008].
    Spada A; Philippe J
    Rev Med Suisse; 2008 Jun; 4(160):1392-4, 1396-7. PubMed ID: 18630062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients.
    Xiao D; Zhang SM; Li X; Yin JY; Gong WJ; Zheng Y; Xu XJ; Lin X; Ji LN; Liu RR; Tang Q; Zhang W; Zhou HH; Han XY; Liu ZQ
    Pharmacogenomics; 2015; 16(14):1621-9. PubMed ID: 26401715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study.
    Blümel JE; Arteaga E; Aedo S; Arriola-Montenegro J; López M; Martino M; Miranda C; Miranda O; Mostajo D; Ñañez M; Ojeda E; Pilnik S; Rojas J; Salinas C; Sosa L; Spritzer PM; Tserotas K; Vallejo MS; Belardo A; Fighera TM; Chedraui P
    Gynecol Endocrinol; 2020 May; 36(5):421-425. PubMed ID: 31994945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Oral hypoglycemic agents and metformin in the treatment of type II non-insulin-dependent diabetes].
    Isnard F
    Sem Hop; 1983 Dec; 59(49):3437-8. PubMed ID: 6320423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biguanide].
    Tanaka Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():647-51. PubMed ID: 22768592
    [No Abstract]   [Full Text] [Related]  

  • 30. Metformin: evidence-based versus rational pharmacotherapy.
    Smits P; Tack CJ
    Neth J Med; 2002 Jul; 60(6):228-30. PubMed ID: 12365465
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
    Andreadis EA; Katsanou PM; Georgiopoulos DX; Tsourous GI; Yfanti GK; Gouveri ET; Diamantopoulos EJ
    Exp Clin Endocrinol Diabetes; 2009 Apr; 117(4):175-80. PubMed ID: 19053032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin in noninsulin-dependent diabetes mellitus.
    Lee AJ
    Pharmacotherapy; 1996; 16(3):327-51. PubMed ID: 8726592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A proof of concept, preliminary study to determine the effect of Yogasnas in controlling type 2 diabetes mellitus in newly detected subjects (when compared to metformin monotherapy).
    Viswanathan V; Chacko PT; Lavanya M; Tilak P
    J Assoc Physicians India; 2006 Dec; 54():965-6. PubMed ID: 17334022
    [No Abstract]   [Full Text] [Related]  

  • 34. Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus.
    Wildasin EM; Skaar DJ; Kirchain WR; Hulse M
    Pharmacotherapy; 1997; 17(1):62-73. PubMed ID: 9017766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin associated with better cardiovascular outcomes than other glycaemic therapies.
    Bloomgarden ZT
    Evid Based Med; 2014 Jun; 19(3):103. PubMed ID: 24393715
    [No Abstract]   [Full Text] [Related]  

  • 36. Metformin: intrinsic vasculoprotective properties.
    Wiernsperger NF
    Diabetes Technol Ther; 2000; 2(2):259-72. PubMed ID: 11469268
    [No Abstract]   [Full Text] [Related]  

  • 37. [Metformin in type 2 diabetes. An extensive observational study confirms the agent as first choice--so far].
    Rydén M
    Lakartidningen; 2011 Jan 26-Feb 1; 108(4):136. PubMed ID: 21365817
    [No Abstract]   [Full Text] [Related]  

  • 38. [Effect of metformin on the expression of tumor necrosis factor-α, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients].
    Andrews M; Soto N; Arredondo M
    Rev Med Chil; 2012 Nov; 140(11):1377-82. PubMed ID: 23677182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High levels of leptin are associated with poor self-rated health in men and women with type 2 diabetes treated with metformin.
    Andreasson AN; Carlsson AC; Wändell PE
    Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):e11-2. PubMed ID: 23337091
    [No Abstract]   [Full Text] [Related]  

  • 40. Benefit of Metformin in COPD: An Effect on Autonomic Nervous System?
    Yasar Z; Erdem F; Talay F
    COPD; 2015 Jun; 12(3):344-5. PubMed ID: 25222022
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.